A Randomized Controlled Study of the NEURESCUE Device as an Adjunct to Advanced Cardiac Life Support
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
Sponsorneurescue
About this trial
The NEURESCUE device is the first intelligent balloon catheter for aortic balloon occlusion (ABO), an emergency technique that supercharges blood flow to the heart and brain within one minute from deployment.
The catheter-based device is delivered via the femoral artery, temporarily inflating a soft balloon in the descending to redirect blood flow towards the upper body.
The purpose of this study is to compare the clinical safety and performance of Advanced Cardiovascular Life Support (ACLS) versus ACLS in combination with Aortic Balloon Occlusion (ABO) using the NEURESCUE device in subjects with cardiac arrest.
Eligibility criteria
Qualifiers
Age ≥18 and ≤80 years
Witnessed arrest
CPR initiated within 7 min of arrest
CPR time less than 40 min at enrollment
Disqualifiers
Traumatic cardiac arrest
Known pregnancy
Known terminal disease
Known do-not-attempt-CPR order
Trial design
Treatments tested in this trial
- Advanced Cardiac Life Support (ACLS)
- Aortic balloon occlusion (ABO)
Treatment groups
84 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov